The Growing Experience with Gilenya® (fingolimod) in Relapsing Multiple Sclerosis

Gilenya® is a once-daily oral disease-modifying therapy (DMT) indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS)*

MORE THAN 204,000 PATIENTS HAVE BEEN TREATED WITH GILENYA® in both clinical trials and the post-marketing setting worldwide

CUMULATIVE EXPOSURE OF APPROXIMATELY 424,000 PATIENT YEARS WITH GILENYA®

Gilenya is now approved in over 80 countries

In June 2014 the European Commission endorsed the CHMP positive opinion recommending to expand the EU label for Gilenya in relapsing-remitting MS (RRMS) to include patients not responding to DMTs beyond interferon.

Gilenya is now approved in over 80 countries

Growing Clinical Trial Evidence With Gilenya

One of the largest Phase III clinical trial programs in RMS was conducted with Gilenya. Accumulation of efficacy and safety data post-marketing continues to reinforce the positve benefit-risk profile of Gilenya.

Growing Real World Evidence With Gilenya

Real-world evidence continues to confirm the benefits of Gilenya in the real-world setting. Data from 264 patients with RMS from the IMS PharMetrics Plus™ Database showed that treatment with Gilenya resulted in 63% fewer relapses per year compared to interferons or glatiramer acetate.

Growing Clinical Trial Evidence With Gilenya

One of the largest Phase III clinical trial programs in RMS was conducted with Gilenya. Accumulation of efficacy and safety data post-marketing continues to reinforce the positive benefit-risk profile of Gilenya.

In clinical trials the most common side effects were headache, increased hepatic enzymes, influenza, sinusitis, diarrhea, back pain, cough.

References


In clinical trials the most common side effects were headache, increased hepatic enzymes, influenza, sinusitis, diarrhea, back pain, cough.